NVO Novo Nordisk A/S
- Official Name: Novo Nordisk A/S
- Headquarters: 800 Scudders Mill Road, PLAINSBORO, NJ 08536, US
- CEO: Lars Jorgensen
- Website: novonordisk.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Lost by 2.564 | (1.182) - 1.382 | ||
| 2025-07-15 | 1R | Lost by 1.938 | (2.019) - (0.081) | ||
| 2025-07-16 | 1R | Lost by 1.386 | (0.444) - 0.942 | ||
| 2025-07-22 | 2 | Lost by 3.178 | (2.159) - 1.019 | ||
| 2025-07-29 | 3 | Lost by 14.791 | (13.934) - 0.857 | ||
| 2025-08-05 | 4 | Won by 15.265 TOTW | 16.343 - 1.078 | ||
| 2025-08-12 | 5 | Won by 8.446 | 9.709 - 1.263 | ||
| 2025-08-19 | 6 | Won by 5.511 TOTW | 10.297 - 4.786 | ||
| 2025-08-26 | 7 | Won by 1.063 | 0.879 - (0.184) | ||
| 2025-09-02 | 8 | Lost by 0.650 | 1.874 - 2.524 | ||
| 2025-09-09 | 9 | Lost by 0.558 | (4.801) - (4.243) | ||
| 2025-09-16 | 10 | Won by 5.861 TOTW | 6.228 - 0.367 | ||
| 2025-09-23 | 11 | Won by 5.538 | 3.997 - (1.541) | ||
| 2025-09-30 | 12 | Lost by 11.395 | (7.175) - 4.220 | ||
| 2025-10-07 | 13 | Won by 5.969 | 5.887 - (0.082) | ||
| 2025-10-14 | 14 | Lost by 8.376 | (4.073) - 4.303 | ||
| 2025-10-21 | 15 | Lost by 2.487 | (3.541) - (1.054) |
Latest News
Benzinga - 2026-09-01
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Benzinga - 2026-09-01
Reported Earlier: 'Novo Nordisk launches Wegovy weight-loss pill in Germany' - Reuters
https://www.reuters.com/legal/litigation/novo-nordisk-launches-wegovy-weight-loss-pill-germany-2026-09-01/
Benzinga - 2026-09-01
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...
SeekingAlpha - 2026-08-31
Novo Nordisk: Why The Price Remains Stubbornly Low (Rating Downgrade)
Novo Nordisk (NVO) is under pressure after Q2 2026 results: Wegovy pill gains but sales missed.
SeekingAlpha - 2026-08-31
Hims & Hers: A Healthcare Behemoth In The Making
Hims & Hers Health is building a vertically integrated consumer health distribution platform. Read why I am bullish about HIMS stock right now.
Show more
SeekingAlpha - 2026-08-27
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
Benzinga - 2026-08-27
10 Health Care Stocks With Whale Alerts In Today’s Session
Benzinga - 2026-08-26
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Benzinga - 2026-08-26
Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
SeekingAlpha - 2026-08-24
Novo Nordisk: Don't Ignore This Dirt-Cheap Buying Opportunity
SeekingAlpha - 2026-08-22
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk
SeekingAlpha - 2026-08-21
Novo Nordisk: The Pill That Could Close The Gap With Lilly
Benzinga - 2026-08-21
10 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-08-19
Novo Nordisk: The Best Value In Pharma
Benzinga - 2026-08-19
Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
Benzinga - 2026-08-19
'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ
Benzinga - 2026-08-17
4 Health Care Stocks With Whale Alerts In Today’s Session
SeekingAlpha - 2026-08-12
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
SeekingAlpha - 2026-08-12
The Market Is (Still) Underestimating Novo Nordisk
Benzinga - 2026-08-11
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
Benzinga - 2026-08-11
Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes
Benzinga - 2026-08-10
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
SeekingAlpha - 2026-08-07
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion
SeekingAlpha - 2026-08-07
Reassessing Inflammation's Link To Cardiovascular Risk
SeekingAlpha - 2026-08-07
Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade
Benzinga - 2026-08-07
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
SeekingAlpha - 2026-08-06
Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
Benzinga - 2026-08-06
Novo Nordisk Scores Major Court Win, Dutch Judge Halts Compounded Semaglutide Nasal Spray
Benzinga - 2026-08-06
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Benzinga - 2026-08-06
Amazon Pharmacy Start Delivery GLP-1 Medications To Eligible Medicare Patients For $50 Per Month
SeekingAlpha - 2026-08-05
Novo Nordisk A/S (NOVO:CA) Q2 2026 Earnings Call Transcript
SeekingAlpha - 2026-08-05
Novo Nordisk A/S 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha - 2026-08-05
Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)
Benzinga - 2026-08-05
CVS Health Retools Its Weight Management Program To Make It Easier For Eligible Adults To Access Clinical Care, Navigate Medication Costs And Get Ongoing Support For GLP-1 Therapy
SeekingAlpha - 2026-08-04
Lower Risk And Higher Total Returns: My 1-Year Review
Benzinga - 2026-08-04
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate
Benzinga - 2026-08-04
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
SeekingAlpha - 2026-08-04
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
Benzinga - 2026-08-04
Novo Nordisk Reports DKK 6.3B Non-Recurring, Non-Cash Impairment Charges In Q2 Related To Intangible Pipeline Assets
SeekingAlpha - 2026-08-04
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For August 2026
Benzinga - 2026-08-03
6 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-08-01
SpaceX's First Earnings Post IPO
SeekingAlpha - 2026-07-31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Benzinga - 2026-07-31
Why Is BioAge Labs Stock Sinking Friday?
Benzinga - 2026-07-31
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
Benzinga - 2026-07-31
Novo Nordisk Announces Ziltivekimab Did Not Translate Into Major Adverse Cardiovascular Events Risk Reduction During Phase 3 Trial In Patients With Atherosclerotic Cardiovascular Disease
SeekingAlpha - 2026-07-29
Novo Nordisk: Too Late For A Great Opportunity
Benzinga - 2026-07-27
4 Health Care Stocks Whale Activity In Today’s Session
SeekingAlpha - 2026-07-27
Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy
SeekingAlpha - 2026-07-27
Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings
SeekingAlpha - 2026-07-26
Novo Nordisk: Initiating Buy, Calling The Bottom
SeekingAlpha - 2026-07-26
Earn 10-15% Potential Income: Monthly Options Series (Aug. 2026)
SeekingAlpha - 2026-07-26
Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That
Benzinga - 2026-07-24
The Wall Street Journal Reported Earlier, Novo Nordisk Filed Preliminary Injunction Request In U.S. Court To Halt Eli Lilly GLP-1 Weight-Loss Drug Advertising During Lawsuit Proceedings
Benzinga - 2026-07-23
Eli Lilly Reports Topline Results From TRIUMPH-2 And TRIUMPH-3 Phase 3 Trials Evaluating Retatrutide; Treatment Met Primary Endpoint, With Substantial Weight Loss In Adults With Obesity
SeekingAlpha - 2026-07-22
Wall Street Breakfast Podcast: Super Micro Heats Up
Benzinga - 2026-07-21
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising
Benzinga - 2026-07-21
Novo Nordisk Takes Legal Action Against Eli Lilly To Stop Multiple Misleading National GLP-1 Advertising Campaigns
SeekingAlpha - 2026-07-20
Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum
SeekingAlpha - 2026-07-18
AI Bubble Risks Make Dividend Stocks Attractive Again
SeekingAlpha - 2026-07-17
Where To Invest Now In AI, Biotech, Small Caps, And Gold
SeekingAlpha - 2026-07-17
Novo Nordisk: The Oral Wegovy Promise
Benzinga - 2026-07-17
Reported Earlier: 'India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease' - Reuters
SeekingAlpha - 2026-07-16
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Fintel - 2026-07-16
JYSKE BANK Downgrades Novo Nordisk A (NVO)
Benzinga - 2026-07-16
Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027
Yahoo - 2026-07-15
Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions
Yahoo - 2026-07-15
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Yahoo - 2026-07-15
Lilly's Obesity Pill Trails Wegovy
Yahoo - 2026-07-15
Sector Update: Healthcare Stocks Advance Late Afternoon
Yahoo - 2026-07-15
NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
Yahoo - 2026-07-15
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Yahoo - 2026-07-15
Novo Nordisk Gets EU Approval for Wegovy Pill for Weight Management
Yahoo - 2026-07-15
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Yahoo - 2026-07-15
European Equities Traded in the US as American Depositary Receipts Advance Wednesday
Benzinga - 2026-07-15
Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
Yahoo - 2026-07-15
Cellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executives
Benzinga - 2026-07-15
Novo Nordisk Receives European Commission's Marketing Authorization For Wegovy Pill To Treat Adults With Obesity
Yahoo - 2026-07-15
How Microsoft (MSFT) Is Deepening Its Enterprise AI Moat With a $2.5 Billion Customer Deployment Initiative
Yahoo - 2026-07-15
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Yahoo - 2026-07-14
Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
Yahoo - 2026-07-14
Novo Nordisk signs pact to assess semaglutide implant
Yahoo - 2026-07-14
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
SeekingAlpha - 2026-07-13
How To Build A $50,000 Dividend Portfolio In Today's Market
Benzinga - 2026-07-13
Novo Nordisk Shares Encouraging Long-Term Data From Hemophilia Program
SeekingAlpha - 2026-07-09
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
SeekingAlpha - 2026-07-09
Novo Nordisk: Why I Don't Think The Story Is Broken
SeekingAlpha - 2026-07-08
Fundsmith Equity Fund: H1 2026 Sales
SeekingAlpha - 2026-07-07
If I Could Only Buy Two High-Yield Stocks In July 2026
SeekingAlpha - 2026-07-07
Novo Nordisk Loses Its Edge, And I'm Downgrading
SeekingAlpha - 2026-07-07
My (Still) 21% Yielding Portfolio Update
SeekingAlpha - 2026-07-07
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Benzinga - 2026-07-07
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant
SeekingAlpha - 2026-07-06
Boston Scientific: The Time Has Come To Catch This Falling Knife
Benzinga - 2026-07-06
AdaptHealth Flags Material Breach After Threat Actor Accessed Patient Management Systems
SeekingAlpha - 2026-07-06
My Top 5 Pharma Stocks Wall Street Ignores
Benzinga - 2026-07-05
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States
SeekingAlpha - 2026-07-04
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals
SeekingAlpha - 2026-07-03
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For July 2026
SeekingAlpha - 2026-07-03
HIMS Breakout Signals Structural Business Transformation
SeekingAlpha - 2026-07-02
Ascendis Pharma: Behind The Stock Surge
SeekingAlpha - 2026-06-30
Like My Stock Portfolio, My Bullish Options Portfolio Crushed The Benchmarks
SeekingAlpha - 2026-06-30
Building A $100,000 Dividend Portfolio With SCHD And July's Top High-Yield Picks
SeekingAlpha - 2026-06-30
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Benzinga - 2026-06-30
Getting Wegovy Or Zepbound Through Medicare? Here's What Patients Need To Know Before Coverage Rolls Out Wednesday
SeekingAlpha - 2026-06-29
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
SeekingAlpha - 2026-06-28
My Top 10 High-Yield Picks For July 2026: One Yields More Than 13%
SeekingAlpha - 2026-06-26
Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)
SeekingAlpha - 2026-06-26
Novo Nordisk: 3 Key Reasons The 'Buy The Dip' Thesis Is Flawed
SeekingAlpha - 2026-06-25
Ozempic Sat Unused For Decades Because Invention Is Not Enough
SeekingAlpha - 2026-06-24
Undercovered Dozen: Blue Owl, IBM, Quantum Computing, Fiserv And More
SeekingAlpha - 2026-06-24
Novo Nordisk: A Strong Yield And Continued Growth
Benzinga - 2026-06-24
White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President'
SeekingAlpha - 2026-06-23
Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities
SeekingAlpha - 2026-06-23
Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying
Benzinga - 2026-06-22
Novo Nordisk Stock Is Surging Monday: What's Driving The Action?
Benzinga - 2026-06-22
CVS Pharmacy Announces New GLP-1 Offerings, Including Expanded Pharmacy Support And A New $49 MinuteClinic Virtual Visit That Connects Eligible Adults With Licensed Clinicians
Benzinga - 2026-06-22
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
Benzinga - 2026-06-18
Hims & Hers Stock Jumps After Barclays Raises Price Target
SeekingAlpha - 2026-06-18
My Top 5 Dividend Picks For June
Benzinga - 2026-06-17
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models
Benzinga - 2026-06-17
7 Health Care Stocks With Whale Alerts In Today's Session
SeekingAlpha - 2026-06-17
Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal
Benzinga - 2026-06-17
Reported June 16, 2026: 'Hacking Group Claims Major Hack Of Novo Nordisk And Attempted $25 Million Extortion' - Reuters News
SeekingAlpha - 2026-06-16
Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain
SeekingAlpha - 2026-06-16
Hims & Hers Enters A New Phase
Benzinga - 2026-06-16
Reported Earlier: 'Novo Nordisk to seek approval soon to sell Wegovy pill in China' - Reuters
Benzinga - 2026-06-15
Doctors Warn Medicare's New Weight-Loss Drug Program Could Lead To A Rush Of Patients That Clinics May Struggle To Handle
SeekingAlpha - 2026-06-15
10 Dividend Growth Stocks: June 2026
SeekingAlpha - 2026-06-15
Novo Nordisk: The Danish Empire Strikes Back
SeekingAlpha - 2026-06-13
Novo Nordisk: Why The Wegovy Pill Doesn't Change My Thesis
SeekingAlpha - 2026-06-12
Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
Benzinga - 2026-06-11
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
Benzinga - 2026-06-11
Novo Nordisk Reports Unauthorized Access IT Security Incident; Core Business Operations Are Not Impacted, Some Personal Data Was Extracted
Benzinga - 2026-06-11
Wegovy Receives Medicines And Healthcare Products Regulatory Agency's Approval To Treat Obesity
SeekingAlpha - 2026-06-10
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven
SeekingAlpha - 2026-06-10
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
SeekingAlpha - 2026-06-08
Novo Nordisk: The Biggest Healthcare Bargain
Benzinga - 2026-06-08
Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs
SeekingAlpha - 2026-06-08
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Benzinga - 2026-06-08
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game'
SeekingAlpha - 2026-06-07
Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript
SeekingAlpha - 2026-06-05
Amgen: Time For An Upgrade? Yes, I Think So
Benzinga - 2026-06-04
8 Stocks Moving In Wednesday's After-Hours Session
Benzinga - 2026-06-04
4 Health Care Stocks With Whale Alerts In Today's Session
SeekingAlpha - 2026-06-04
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For June 2026
Benzinga - 2026-06-04
Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy
Benzinga - 2026-06-03
10 Health Care Stocks Whale Activity In Today's Session
SeekingAlpha - 2026-06-03
Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027
SeekingAlpha - 2026-06-03
Wall Street Breakfast Podcast: Bitcoin's Great Withdrawal
SeekingAlpha - 2026-06-02
Madrigal Pharmaceuticals Could Become The Next Vertex
SeekingAlpha - 2026-06-01
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)
SeekingAlpha - 2026-05-29
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
SeekingAlpha - 2026-05-28
Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win
SeekingAlpha - 2026-05-28
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
Benzinga - 2026-05-28
CVS Expands GLP-1 Options For Members, Including The Reintroduction Of Zepbound As A Covered Medication
Benzinga - 2026-05-22
Novo Nordisk Gets European Commission Extension To Marketing Authorisation For Wegovy In EU To Add An Oral Formulation For Weight Management
SeekingAlpha - 2026-05-21
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
SeekingAlpha - 2026-05-20
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)
SeekingAlpha - 2026-05-20
Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant
SeekingAlpha - 2026-05-19
Eli Lilly: Novo Nordisk Was Just A Warm-Up
Benzinga - 2026-05-19
Novo Nordisk To Unveil Data Showing Semaglutide Tackles The Liver Disease Crisis Affecting About 1 In 3 People Living With Overweight And Obesity Worldwide
Benzinga - 2026-05-19
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Benzinga - 2026-05-18
'Drug Companies Spurned by Supreme Court on Price Negotiation Law' - Bloomberg News
SeekingAlpha - 2026-05-18
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
SeekingAlpha - 2026-05-15
Hims & Hers Health: The Stock Is On Sale, Buy It
SeekingAlpha - 2026-05-14
Novo Nordisk: The First Fruits Of Labor
SeekingAlpha - 2026-05-14
Hims & Hers Health Is Likely Dead Money
SeekingAlpha - 2026-05-14
Novo Nordisk: Why I Won't Upgrade
Benzinga - 2026-05-14
Trump's Drug Pricing Plan Gains Surprise Democratic Ally— Peter Welch Vows To 'Make It Happen'
Benzinga - 2026-05-13
Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today
Benzinga - 2026-05-13
Novo Nordisk Highlights New Wegovy Pill Data
Benzinga - 2026-05-13
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
SeekingAlpha - 2026-05-13
April CPI Inflation: Brace For Margin Pressure
SeekingAlpha - 2026-05-13
Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain
Benzinga - 2026-05-12
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction
Benzinga - 2026-05-12
Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts
Benzinga - 2026-05-12
Novo Nordisk Says Wegovy Showed An Average 22.6% Weight Loss For Premenopausal Women With Obesity, With More Than 41% Achieving 25% Or More Weight Loss
Benzinga - 2026-05-11
Cellular Intelligence To Acquire Novo Nordisk's STEM-PD Parkinson's Cell Therapy Program; No Financial Terms Disclosed
Benzinga - 2026-05-10
Trump Admin Proposes New IVF Benefit To Expand Fertility CoverageThrough Employers
SeekingAlpha - 2026-05-10
Novo Nordisk: Flipping The Script
SeekingAlpha - 2026-05-07
Wall Street Lunch: DOJ, CFTC Investigate Suspicious $2.6B Oil Trades Tied To Iran Conflict Headlines
Benzinga - 2026-05-07
CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026
Benzinga - 2026-05-07
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites
Benzinga - 2026-05-06
Earnings Scheduled For May 6, 2026
SeekingAlpha - 2026-05-06
Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It
Benzinga - 2026-05-06
S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today
SeekingAlpha - 2026-05-06
Novo Nordisk: Misread Q1 Earnings, Mispriced Stock
Benzinga - 2026-05-06
Is Semi Mania Leading To A 2000-Style Crash? US-Iran Proposal Lifts Market, Pressures Oil
SeekingAlpha - 2026-05-06
Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript
Benzinga - 2026-05-06
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report
Benzinga - 2026-05-06
'Novo Sees Generic Ozempic Delayed in China Until Next Year' - Bloomberg
Benzinga - 2026-05-06
Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook
ChartMill - 2026-05-06
Record Highs, Punished Results, and One Very Consequential Apple Rumor
SeekingAlpha - 2026-05-06
Novo Nordisk A/S 2026 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-05-06
Novo Nordisk Raises FY2026 Sales Guidance from $40.463B-$44.317B to $42.389B-$46.243B vs $45.440B Est
Benzinga - 2026-05-06
Novo Nordisk Q1 Adj. EPS $1.04 Beats $0.87 Estimate, Sales $15.173B Beat $11.130B Estimate
SeekingAlpha - 2026-05-05
Viking Therapeutics: Market Betting On Big Upside Through 2030
SeekingAlpha - 2026-05-05
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For May 2026
Benzinga - 2026-05-05
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 15 Years
SeekingAlpha - 2026-05-05
AI Revolutionizing Biopharma: Faster, Better, Cheaper
SeekingAlpha - 2026-05-05
Novo Nordisk: My Q1 Preview And Why I'm Doubling Down
SeekingAlpha - 2026-05-05
Eli Lilly: No Big Gap To Competition
SeekingAlpha - 2026-05-04
Novo Nordisk: A Generational Buying Opportunity Ahead Of Q1 Earnings
Benzinga - 2026-05-04
GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...'
Benzinga - 2026-05-01
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
Benzinga - 2026-05-01
10 Health Care Stocks With Whale Alerts In Today's Session
SeekingAlpha - 2026-05-01
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims
Benzinga - 2026-05-01
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules
SeekingAlpha - 2026-05-01
Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)
Benzinga - 2026-05-01
Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US
Benzinga - 2026-05-01
GoodRx Providing Access To Novo Nordisk's Ozempic Pill At $149/Month
SeekingAlpha - 2026-05-01
Pfizer: Why You Should Double Down Into Q1
Benzinga - 2026-04-30
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List; Finds No Clinical Need For Bulk Compounding Of These Drugs
SeekingAlpha - 2026-04-30
Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview)
Benzinga - 2026-04-30
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…'
Benzinga - 2026-04-29
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
SeekingAlpha - 2026-04-28
Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch
Benzinga - 2026-04-28
'Canada Approves Its First Generic Version of Novo's Ozempic' - Bloomberg News
Benzinga - 2026-04-27
Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy
Benzinga - 2026-04-27
4 Health Care Stocks Whale Activity In Today's Session
SeekingAlpha - 2026-04-27
Regeneron: Catching Another Wind
ChartMill - 2026-04-27
Intel Resets the Clock on the Chip Sector and the Weekend Complicated Everything Else
SeekingAlpha - 2026-04-24
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1
SeekingAlpha - 2026-04-24
Depressed Equities That May Be Worth Investigating Further
Benzinga - 2026-04-24
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
Benzinga - 2026-04-24
Novo Nordisk shares are trading higher after the company announced results of an oral semaglutide trial in children aged 10-17 years with type 2 diabetes.
SeekingAlpha - 2026-04-24
Abbott Laboratories: Buying A Healthcare Giant On Sale
Benzinga - 2026-04-23
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch
Benzinga - 2026-04-23
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Benzinga - 2026-04-23
Novo Nordisk Oral Semaglutide In PIONEER TEENS Trial In Children 10–17 With Type 2 Diabetes Achieved 0.83% Blood Sugar Reduction Vs Placebo At 26 Weeks
SeekingAlpha - 2026-04-22
Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It?
Benzinga - 2026-04-21